|Application ||WB, IHC-P, IF, E|
|Other Accession||NP_612464, 19923989|
|Reactivity||Human, Mouse, Rat|
|Calculated MW||Predicted: 27 kDa |
Observed: 27 kDa
|Application Notes||CTHRC1 antibody can be used for detection of CTHRC1 by Western blot at 1 - 2 µg/mL. Antibody can also be used for immunohistochemistry starting at 5 µg/mL. For immunofluorescence start at 20 µg/mL.|
|Target/Specificity||CTHRC1; CTHRC1 antibody is human, mouse and rat reactive. At least two isoforms of CTHRC1 are known to exist; this antibody will detect only the larger isoform.|
|Reconstitution & Storage||CTHRC1 antibody can be stored at 4℃ for three months and -20℃, stable for up to one year.|
|Precautions||CTHRC1 Antibody is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||May act as a negative regulator of collagen matrix deposition.|
|Cellular Location||Secreted, extracellular space, extracellular matrix|
|Tissue Location||Isoform 1 is expressed in calcified atherosclerotic plaque and chondrocyte-like cells|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
The Collagen triple helix repeat-containing protein (CTHRC1) is a glycosylated, secreted protein that is transiently expressed in the arterial wall in response to injury where it is thought to contribute to vascular remodeling by inhibiting collagen expression and deposition and promoting cell migration (1). CTHRC1 is highly expressed multiple human cancers, including pancreatic cancer where it plays a significant role in the progression and metastasis of the disease by regulating migration and adhesion of tumors cells (2). CTHRC1 overexpression can also be used as an independent prognostic marker in gastric cancer (3). Mutations at this locus have been associated with Barrett esophagus and esophageal adenocarcinoma (4).
Pyagay P, Heroult M, Wang Q, et al. Collagen triple helix repeat containing 1, a novel secreted protein in injured and diseased arteries, inhibits collagen expression and promotes cell migration. Circ. Res. 2005; 96:261-8.
Park EH, Kim S, Jo JY, et al. Collagen triple helix repeat containing-1 promotes pancreatic cancer progression by regulating migration and adhesion of tumor cells. Carcinogenesis 2013; 34:694-702.
Gu L, Liu L, Zhong L, et al. Cthrc1 overexpresion is an independent prognostic marker in gastric cancer. Hum. Pathol. 2014; 45:1031-8.
Orloff M, Peterson C, He X, et al. Germline mutations in MSR1, ASCC1, and CTHRC1 in patients with Barrett esophagus and esophageal adenocarcinoma. JAMA 2011; 306:410-9.
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at firstname.lastname@example.org.